[ad_1]
BENGALURU (Reuters) – Indian drugmaker Zydus Cadila said on Friday it signed a non-exclusive agreement with Gilead Sciences Inc to manufacture and market antiviral drug remdesivir, the first treatment to show improvement in COVID-19 trials.
Reporting by Anuron Kumar Mitra in Bengaluru
Our Standards:The Thomson Reuters Trust Principles.
[ad_2]
Source link